BMN Entertainment, a leader in comedy production, is excited to announce the return of the "We Them Ones"Comedy Tour in 2025. The "We Them Ones Comedy Tour" is more than just a comedy show; it is a ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. The consolidation of the Spanish banking sector continues apace, after state-controlled Bankia agreed to take ...

BioMarin is evolving into a scalable rare-disease commercialization platform, leveraging its infrastructure for new product launches and lifecycle management. The $4.8B Amicus acquisition adds ...

ENERGY 3 study met 1 of 2 co-primary endpoints in children with ENPP1 deficiency Treatment with BMN 401 led to statistically significant increases in plasma inorganic pyrophosphate (PPi) concentration ...

SAN RAFAEL, Calif., Sept. 6, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the U.S Food and Drug Administration (FDA) placed a clinical hold on the BMN 307 ...

Competition is coming for BioMarin’s potential blockbuster Voxzogo, but the California biotech may be able to answer with a longer-acting version of the C-type natriuretic peptide (CNP), which treats ...

BioMarin Pharmaceutical has reported that its pivotal Phase III ENERGY 3 trial assessing BMN 401 in children aged one to 12 years with ectonucleotide pyrophosphatase ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

This trial is no longer recruiting patients. We hope to add results when they are available. This study is learning more about a new drug called BMN 673, which hasn’t been tested in people before. It ...